Access to medicinal cannabis for patients to be simplified Bern, 22.06.2022 – The Federal Council wants to make it easier for patients to access medicinal cannabis. It therefore decided at its meeting on June 22 to lift the ban on cannabis for medicinal purposes from the Narcotics Act. Medical prescriptions no longer require an exceptional…
Fibromyalgia is a chronic pain syndrome, often accompanied be sleeping disturbances, chronic musculoskeletal pain, fatigue, and mood disturbances. The pathogenesis of fibromyalgia is not clear. It usually affects women more than men and has a genetic preponderance. Fibromyalgia can have physical and psychological, impacts on patients. Unfortunately, in most patients, fibromyalgia is chronic. Usual medications…
Over last few years researchers’ attention has been focused on use of medical cannabis due to global regulatory loosening. This fact significantly increased cannabinoid therapeutics analytical data in psychiatric field. Many of them suggest that cannabinoid might improve depressive disorders and symptoms, anxiety disorders, attention-deficit hyperactivity disorder, Tourette syndrome, post-traumatic stress disorder, or psychosis. Moreover,…
The SRF documentary on Medical Cannabis provides an overview on the current market situation Key takeouts: good results on patients using the medicine high prices for patient due to 1 company dominant position flowers are not yet available as medicine (it will only be available with the #pilotprojects medical Cannabis still need to evolve from…
Epilepsy is one of the most common non-transmissible neurological diseases. It is defined as a brain disorder that predisposes to seizures and has associated physical, psychological and social consequences. Approximately one-third of patients with epilepsy have seizures that are resistant to antiepileptic medications. These patients do not respond well to the conventional antiepileptic drugs. Moreover,…
March 24th 2022 – General decision of the Swiss Chemicals Notification Authority concerning the placing on the market of fragrances / perfume oil containing CBD, pursuant to Art. 10 (1) and (2) in connection with Art. 1 (1) to (3) of the Pest Control Products Act. A Federal decision on banning CBD from fragrances (chemical…
Starting this summer, it will be easier to get a prescription for medical cannabis. But watch your wallet, because it won’t be automatically reimbursed. Cannabis-based medicines will soon be available by prescription, without the need for exceptional authorization from the Federal Office of Public Health (FOPH). This legislative change will probably come into force in…
On February 1st 2022, the Swiss Association of Cantonal Chemists, announced in a press release that, in Switzerland, the vast majority of products sold containing the cannabis extract cannabidiol (CBD) do not meet legal requirements. It was relayed across many media channels, such as swissinfo stating that Most CBD cannabis products fail to meet standards. However, these findings do not apply to the medical/therapeutic cannabis.
Several recent laboratory studies of cannabidiol, or CBD, have shown promising results in the context of prevention the coronavirus infection. The study performed by the team of Marsha Rosner of the University of Chicago (USA) recently published evidence that CBD could block the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) responsible for COVID-19. Their study published…
Content of the publication: A new study regarding the prevention of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection responsible for COVID-19 was published on January 10, 2022, in the scientific journal “The Journal of Natural Products”[1]. Researchers from the Oregon Health and Science University in Portland (USA) have demonstrated the potential of cannabinoids to…
No products in the cart.